Articles tagged with Sars Cov 2
Researchers analyzed 2.9 million households and found small, informal gatherings like birthdays contribute to SARS-CoV-2 transmission. Children's birthday parties are a potentially significant source of COVID-19 spread.
Researchers mapped epitopes in SARS-CoV-2 to identify potential cross-reactive antibodies, expanding vaccine and therapeutic development options. The study suggests new targets for diagnostics and improved treatments against SARS-CoV-2 and other coronaviruses.
A case of multisystem inflammatory syndrome in an adult who recovered from COVID-19 is reported, highlighting the importance of considering this rare but possible complication. Prompt treatment helped recover the patient. The authors suggest encouraging reporting of cases to facilitate research and improve outcomes.
Researchers from Charité and University of Bonn identify four substances that inhibit SARS-CoV-2 replication in host cells, including niclosamide, a tapeworm drug. These findings suggest potential new treatment against COVID-19.
Commensal gut bacteria like Bifidobacteria have been found to produce compounds that inhibit SARS-CoV-2. The researchers screened dominant gut bacteria for activity against the virus and discovered several compounds with potential therapeutic value.
Researchers investigated two SARS-CoV-2 variants and found that patients with these variants were less likely to be asymptomatic. Despite no increase in viral load, the variants showed higher transmissibility, leading to increased hospitalization rates.
A study of 300 rheumatism patients found 9% SARS-CoV-2 antibody positivity rates for IgG, IgM, and IgA, with higher titres in symptomatic patients and those with obesity and multiple comorbidities. The study confirms that the true spread of SARS-CoV-2 infection is broader than previously thought, particularly among vulnerable populations.
Researchers from the University General Hospital in Valencia, Spain, analyzed the local transmission pattern of SARS-CoV-2. The study found that the virus was mainly spread through human-to-human contact, with cases primarily reported in urban areas.
Researchers develop nanodecoys made from human lung spheroid cells that bind to and neutralize SARS-CoV-2, accelerating viral clearance and reducing lung injury. The therapy could be effective against emerging variants of the virus.
A new study found that SARS-CoV-2 can infect the testes of infected hamsters, a finding with implications for men's health. The virus was detected in the testes of all infected hamsters during the first week but tapered off over time.
Researchers found that vaccination with an mRNA vaccine induces antibody responses that would protect humans from infection with the gamma/P.1 variant, while hamsters previously infected with earlier strains were also protected nine months later. Previous SARS-CoV-2 infection and vaccines based on earlier strains still provide protecti...
Researchers at Osaka University have created a new, highly sensitive test for the SARS-CoV-2 virus that uses artificial intelligence and nanopore technology. The test platform achieved a sensitivity of 90% and specificity of 96% for SARS-CoV-2 detection in just five minutes using clinical saliva samples.
Researchers identified three previously undiagnosed COVID-19 cases in a UK hospital from throat swabs collected between January and March 2020. The study suggests that testing should have been made available to hospital patients with compatible symptoms earlier in the pandemic.
Researchers at the University of Illinois Chicago have developed a graphene-based sensor that can detect SARS-CoV-2 virus in laboratory experiments. The sensor uses atomic-level vibrations to identify COVID-positive samples, with results evident in under five minutes.
A study of 3,758 individuals found that those with diabetes, obesity, rheumatologic disease, or organ transplants had longer positive PCR test results. The median length of time for negative results was 16-22 days in immunocompromised and non-immunocompromised groups respectively.
A new study reveals that wastewater sequencing can detect emerging SARS-CoV-2 variants like B.1.1.7 up to 8 weeks before they become prevalent in clinical cases. This early warning system provides a more accurate picture of virus circulation among humans, including asymptomatic individuals.
Researchers analyzed 24,000 blood samples and multiple antibody testing platforms to discover SARS-CoV-2 infections in five states earlier than reported. The findings expand on previous studies suggesting the virus was present in the US as early as December 2019.
A study by Yale researchers found that the common cold virus can trigger an immune response that halts replication of the SARS-CoV-2 virus. Exposure to rhinovirus was shown to protect against COVID-19 infection, with the immune system responding rapidly to the threat.
The study found a significant association between SARS-CoV-2 RNA levels and symptom severity in patients with the virus. Researchers discovered that higher RNA levels were linked to more severe symptoms, suggesting a possible correlation between viral load and disease progression.
Care home residents over 70 have a delayed and weaker immune response to vaccines compared to younger individuals, making them more susceptible to SARS-CoV-2 infections. This phenomenon has been confirmed by researchers from Charité - Universitätsmedizin Berlin.
The Pfizer COVID-19 vaccine provides strong protection against SARS-CoV-2 variants, including those from South Africa and Brazil. However, monoclonal antibody therapy may be less effective against these variants.
A recent US study estimated the incidence of multisystem inflammatory syndrome in children among people with SARS-CoV-2 infection. The study found a significant association between MIS-C and severe COVID-19, highlighting the need for vigilance and prompt medical attention.
Researchers analyzed brain scans of 193 COVID-19 patients, finding a link between brain imaging and the virus's presence in cerebrospinal fluid. The study suggests hyperintense lesions and leptomeningeal enhancement are indicative of inflammation rather than infection.
Researchers found that a single-shot COVID-19 vaccine generated strong immune responses against all SARS-CoV-2 variants. The study suggests non-neutralizing antibodies and T cell responses may contribute to protection against COVID-19, particularly in regions with variant prevalence.
Researchers found SARS-CoV-2 on hospital floors and surfaces, especially after patient onset of symptoms. The virus was often accompanied by the bacteria Rothia, which strongly predicted its presence.
The SARS-CoV-2 papain-like protease (PLpro) inactivates human proteins crucial for immune response, cardiovascular function and blood clotting. This link may explain COVID-19 symptoms of heart damage, blood clots and inflammation.
New research from Imperial College London found that warmer temperatures and higher population density contribute to SARS-CoV-2 transmission. However, policy interventions such as lockdowns and social distancing remain the most important drivers of disease spread, even in seasonal variations.
Researchers found that intermediate-sized respiratory droplets emitted while speaking can carry significant amounts of virus and remain suspended in air for minutes. These 'speech droplets' pose a considerable risk of SARS-CoV-2 transmission, particularly in enclosed spaces without proper ventilation.
A real-world study found the first dose of the BNT162b2 (BioNTech/Pfizer) vaccine to be highly effective in preventing SARS-CoV-2 infection 13 to 24 days after immunization. The study revealed a significant reduction in infection rates among vaccinated individuals, highlighting the vaccine's effectiveness in real-world settings.
Researchers found COVID-19 causes a wide range of organs, including the kidneys, resulting in acute kidney injury (AKI) with significant mortality rates. Studies showed viruses were directly detected in kidneys of deceased patients, correlating with age and comorbidities.
A new SARS-CoV-2 variant, T478K, has been identified in over 50% of viruses in North America, particularly in Mexico, where it spreads rapidly among all age groups. The mutation in the Spike protein alters its interaction with the human receptor ACE2, potentially hindering drug efficacy and immune system antibodies.
Researchers at George Mason University discovered that the over-the-counter drink Respiratory Detox Shot (RDS) may broadly inhibit respiratory viruses such as influenza. RDS contains nine herbal ingredients traditionally used in Eastern medicine to manage lung diseases.
Researchers at Tokyo University of Science found a promising treatment for COVID-19 using the drugs cepharanthine and nelfinavir, which show potential in suppressing SARS-CoV-2. Computational models predict combined therapy could hasten clearance of the virus from patients' lungs.
A study of over 1,500 UK dental professionals found 16.3% had SARS-CoV-2 antibodies, highlighting the occupational risk of infection. The study also showed ethnicity was a significant risk factor and that COVID-19 vaccination provided rapid and high antibody responses.
Researchers tracked mobile phone data from millions of users in US metropolitan areas, finding that lower-income neighborhoods had significantly less time at home during the lockdown. Education level also played a role, with higher-income neighborhoods and those with more college degrees spending more time at home.
Researchers found that SARS-CoV-2 infected various organs in children, leading to a wide range of clinical manifestations, including abdominal pain, heart failure, and seizures. The study suggests that the virus's direct action on tissues is associated with an exacerbated inflammatory response in children.
The study found diABZI to be highly effective in preventing severe COVID-19 in mice infected with SARS-CoV-2. The drug stimulates interferon signaling, reducing viral loads and cytokine production in the lungs.
A study found that cancer patients had lower SARS-CoV-2 antibody levels compared to healthcare workers. Health care workers in Japan had higher SARS-CoV-2 antibody levels, indicating a possible immune response to the virus.
Researchers investigated mRNA vaccination response in Israeli cancer patients. Patients with cancer who received the vaccine showed seropositivity, indicating an immune response against SARS-CoV-2. The study aimed to assess the safety and efficacy of mRNA vaccines in this vulnerable population.
A study in Lombardy, Italy found that SARS-CoV-2 reinfections are rare events, with patients who have recovered from COVID-19 having a lower risk of reinfection. The observation was limited by the timing of the study, as variants had not yet spread.
Scientists from Scripps Research have discovered a cross-reactive coronavirus antibody that neutralizes SARS-CoV-1 and other coronaviruses, including those causing the common cold. The finding is a promising development for the eventual development of a pan-coronavirus vaccine.
Researchers developed a DNA vaccine encoding SARS-CoV-2 spike protein, which induced long-lasting antibodies in mice and hamsters. The vaccine showed protective efficacy against COVID-19 infection in hamsters, with no loss of body weight or viral RNA in their lungs.
A new study found that an inhalable nanobody-based treatment can effectively prevent and treat SARS-CoV-2 infections in Syrian hamsters. The treatment, PiN-21, prevents significant weight loss and eliminates the virus after 10 days, regardless of the original route of viral entry.
A new study by Brigham and Women's Hospital uses an ultrasensitive test to detect circulating antigen in vaccinated individuals, showing a strong immune response. The test found evidence of low viral protein levels followed by antibody production and clearance of proteins from the blood.
Researchers analyzed PCR samples from over 25,000 COVID-19 cases to estimate infectiousness. Viral loads were found to be lowest in young children and increased with age. The study provides new insights into the B.1.1.7 variant and highlights individual differences in infectiousness.
Researchers from La Jolla Institute for Immunology have found that human T cells can target more than 1,400 sites on the SARS-CoV-2 virus, revealing a broad and diverse immune response. This analysis can help monitor effective responses to COVID-19 vaccines and track variations in T cell responses.
Researchers at the University of Oxford and their international team have discovered how SARS-CoV-2 RNA interacts with host cells, paving the way for new therapeutic strategies. The study found that SARS-CoV-2 hijacks more than 100 cellular proteins to replicate, providing a potential target for antiviral treatments.
Researchers developed a method called SARSeq that enables large groups to be tested for SARS-CoV-2 with the same sensitivity as regular PCR tests. The method processes up to 36,000 samples in less than 48 hours and is highly specific and scalable.
Researchers at Keck School of Medicine of USC have identified GRP78 as a molecular chaperone that plays a crucial role in the spread of SARS-CoV-2, offering a potential new therapy to combat COVID-19. Targeting GRP78 with therapies could provide additional protection against COVID-19 and its variants.
Researchers at Osaka University discovered that neutralizing antibodies and infection-enhancing antibodies are produced after SARS-CoV-2 infection. Infection-enhancing antibodies increase infectivity, which is more common in severe COVID-19 patients.
Researchers at Hokkaido University have identified a unique defense mechanism against SARS-CoV-2, involving the viral pattern recognition receptor RIG-I. Upregulating RIG-I expression may help predict COVID-19 patient outcomes and could be a potential strategy to control SARS-CoV-2 infection.
A study examining SARS-CoV-2 infection risk and socioeconomic disadvantage among a Mayan-Latinx population in California revealed significant variation in infection rates. The researchers identified socioeconomic factors as a key predictor of increased risk, highlighting the need for targeted interventions to address health disparities.
Mathematical models predict that COVID-19 severity will decrease as populations develop immunity, with mild cases becoming the norm. The research suggests adaptations in immune response over time rather than virus changes may drive this shift.
A new study reveals key details of how SARS-CoV-2 variants escape the immune response created by natural infection or vaccination. The research highlights that several mutations are clustered in one site on the spike protein, disrupting antibody binding and neutralization.
Researchers mapped COVID-19 viral lineages across New York City during its first wave of epidemic. The study found that the borough of Queens played a significant role in SARS-CoV-2 transmission due to high local circulation of viral lineages.
Face masks are highly effective in preventing the spread of COVID-19 in virus-limited environments, but more advanced masks and ventilation are required in virus-rich settings. High compliance is necessary for mask effectiveness, with at least 60-70% required for surgical masks.
This study describes clinical characteristics and outcomes of adults with SARS-CoV-2 infection who developed multisystem inflammatory syndrome. Key findings include the prevalence of comorbidities and predictors of severe disease.
A US study published in The BMJ found that 14% of adults with COVID-19 developed new conditions requiring medical care during the post-acute phase. Risk was higher in younger adults and those with pre-existing conditions, but persisted even among those who recovered at home.
A rapid antigen test for SARS-CoV-2 in saliva has been developed, showing high accuracy and efficiency for mass-screening. The test uses chemiluminescent enzyme immunoassay (CLEIA) and can detect the virus within an hour.
The European Society of Endocrinology has confirmed the strong links between hormones and COVID-19, with evidence suggesting an 'endocrine phenotype' of the disease. Diabetes and obesity have emerged as comorbidities associated with severity and mortality of COVID-19.